Onkourologiya最新文献_第9页

Molecular subtypes of bladder cancer and first success in personalized treatment 膀胱癌分子亚型和个体化治疗的首次成功

IF 0.1

Onkourologiya Pub Date : 2020-04-23 DOI: 10.17650/1726-9776-2020-16-1-106-113

V. Osetnik, E. Mamizhev, I. B. Dzalilov, A. Artemyeva, V. Kushnarev

引用次数: 1

The validation of threshold decision ruls and calculator for APhiG algoritm for clarification of prostate cancer staging before treatment 阈值决策规则及APhiG算法用于明确前列腺癌治疗前分期的计算器验证

IF 0.1

Onkourologiya Pub Date : 2020-04-23 DOI: 10.17650/1726-9776-2020-16-1-43-53

N. Sergeeva, T. Skachkova, N. Marshutina, K. M. Nushko, I. Shevchuk, M. Nazirov, B. Alekseev, S. Pirogov, E. Yurkov, V. Gitis, A. Kaprin

引用次数: 1

Review of the article “Choice of urine deriv ation method after r adical cystectomy in the high anesthesiological risk gr oup” 《麻醉高危人群根治性膀胱切除术后尿液提取方法的选择》一文综述

IF 0.1

Onkourologiya Pub Date : 2020-04-23 DOI: 10.17650/1726-9776-2020-16-1-99

K. Figurin

引用次数: 0

Review of the article “Oncological results of neoadjuvant chemohormonal therapy in patients with high and very high-risk prostate cancer” “高、高危前列腺癌患者新辅助激素化疗的肿瘤学结果”一文综述

IF 0.1

Onkourologiya Pub Date : 2020-04-23 DOI: 10.17650/1726-9776-2020-16-1-64-65

K. M. Nussko

引用次数: 0

Radium chloride [223Ra] for patients with prostate cancer and skeletal metastases. Clinical recommendations 氯化镭[223Ra]用于前列腺癌和骨骼转移患者。临床建议

IF 0.1

Onkourologiya Pub Date : 2020-04-23 DOI: 10.17650/1726-9776-2020-16-1-114-123

T. Kochetova, V. Krylov, K. Petrosyan, O. Karyakin, V. Biryukov, B. Alekseev, V. Matveev, S. A. Ivanov, A. Kaprin

{"title":"Radium chloride [223Ra] for patients with prostate cancer and skeletal metastases. Clinical recommendations","authors":"T. Kochetova, V. Krylov, K. Petrosyan, O. Karyakin, V. Biryukov, B. Alekseev, V. Matveev, S. A. Ivanov, A. Kaprin","doi":"10.17650/1726-9776-2020-16-1-114-123","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-1-114-123","url":null,"abstract":"Radiopharmaceuticals previously used to treat patients with metastatic castrate-resistant prostate cancer and skeletal metastases were positioned as means to suppress pain, reduce analgesics consumption and improve the quality of life. They were usually administered once in case of progressive pain syndrome. Radium chloride [223Ra] is registered to treat patients with castrate-resistant prostate cancer and multiple skeletal metastases, but without visceral metastases. The ALSYMPCA study showed a significantly increased overall survival in the group receiving radium chloride [223Ra] compared with placebo. This became the basis to register the drug, as well as to include the treatment into the clinical guidelines of professional associations in various countries of the world. The secondary endpoints of the ALSYMPCA study were evaluation of the quality of life, the influence of radium chloride [223Ra] on pain severity, the dynamics of tumor and biochemical markers, and the time to the first skeleton associated complication. Thus, the main goal of radium chloride [223Ra] therapy is to prolong patients’ life, and it can be prescribed to those with or without pain syndrome. The data served as the basis for widespread use of radium chloride [223Ra] to treat patients with castrate-resistant prostate cancer and skeletal metastases","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2020-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67755651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influence of surgical approach on enhanced recovery after surgery in laparoscopic radical nephrectomy 手术入路对腹腔镜根治性肾切除术术后增强恢复的影响

IF 0.1

Onkourologiya Pub Date : 2020-04-23 DOI: 10.17650/1726-9776-2020-16-1-35-42

D. Perlin, I. Dymkov, E. Davydova, A. Shmanev, A. Perlina

{"title":"Influence of surgical approach on enhanced recovery after surgery in laparoscopic radical nephrectomy","authors":"D. Perlin, I. Dymkov, E. Davydova, A. Shmanev, A. Perlina","doi":"10.17650/1726-9776-2020-16-1-35-42","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-1-35-42","url":null,"abstract":"Background. Аdvantages of the retroperitoneal approach, successfully applied in some clinics, but only a few studies on direct comparison of laparoscopic and retroperitoneoscopic radical nephrectomy.The study objective: to compare transperitoneal and retroperitoneal access during laparoscopic radical nephrectomy.Materials and methods. The study included 332 patients who underwent laparoscopic radical nephrectomy for renal cell carcinoma T1a–T3b. Transperitoneal access – 134, retroperitoneal – 198.Results. The mean time of laparoscopic radical nephrectomy, as well as the time before clipping of the renal artery were significantly less in retroperitoneal access (161 ± 59 and 30 ± 24 min, respectively, compared with 178 ± 65 and 38 ± 39 min – with transperitoneal). The number of removed lymph nodes, and the number of patients detected with “positive” lymph nodes, and death from progression of disease was not significantly different between the groups transperitoneal and retroperitoneal access with an average follow-up period, 42.5 and 47.8 months respectively.Conclusion. Despite the lower popularity retroperitoneal access, the method has advantages in enhanced recovery after surgery (ERAS), particular frequency of general perioperative complications, duration of epidural anesthesia, time of normalization of bowel function and length of hospital stay compared with transperitoneal access. The method is preferred for the old age and patients with comorbidity, especially of the cardiovascular system and respiratory organs.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2020-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67755979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tissue synthesis of some components of the renin-angiotensin system in hypertensive patients with localized kidney cancer 高血压合并局部肾癌患者肾素-血管紧张素系统某些组分的组织合成

IF 0.1

Onkourologiya Pub Date : 2020-04-23 DOI: 10.17650/1726-9776-2020-16-1-27-34

R. Osokin, I. Aboyan, E. F. Komarova, A. Maksimov, E. Komarova

{"title":"Tissue synthesis of some components of the renin-angiotensin system in hypertensive patients with localized kidney cancer","authors":"R. Osokin, I. Aboyan, E. F. Komarova, A. Maksimov, E. Komarova","doi":"10.17650/1726-9776-2020-16-1-27-34","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-1-27-34","url":null,"abstract":"Background. In the last decade, the relationship between arterial hypertension and the risk of developing kidney cancer (KC) has been pointed out. Some studies have shown that the metabolic imbalance of the components of the renal renin-angiotensin system (RAS) is associated with the development and progression of KC.Objective: to study the state of RAS in tumor and peritumoral tissues in patients with KC on the background of arterial hypertension. Materials and methods. In patients with localized KC T1N0M0 and grade I–II arterial hypertension without special treatment (n = 40) in the samples of tumor, peritumoral and histologically unchanged tissue, the levels of angiotensins 1, 2, 1–7 (AT1, AT2, AT(1–7)) of angiotensin-converting enzymes (ACE, ACE2) were determined by ELISA. The comparison group consisted of patients with RC without impaired blood pressure (n = 55).Results. In patients with KC, the level of AT1 is 1.5 times higher (p <0.05), and AT2 is 1.6 times higher (p <0.05) in tumor tissue against the background of unchanged content in peritumoral tissue compared with histologically unchanged tissue. The level of ACE is higher than histologically unchanged tissue by 2.7 times, ACE2 – by 1.6 times (in all cases p <0.05), and in peritumoral tissue it is identical in histologically unchanged tissue.In patients with KC and arterial hypertension, the level of AT1 and AT2 in the tumor tissue is 1.8 times higher (p <0.05) and 2.1 times (p <0.01), respectively, the content of AT(1–7) is 1.6 times (p <0.01). In peritumoral tissue, AT1 is 1.6 times higher (p <0.01) and AT2 is 1.9 times higher (p <0.05). The level of AT(1–7) in the peritumoral tissue is identical to the values in the histologically unchanged tissue. The content of ACE and ACE2 in tumor tissue is 3.6 and 2.9 times higher, respectively, and in peritumoral tissue is identical to that in tumor tissue. Correlation analysis revealed a reliable direct relationship in the studied groups for all parameters, while in the peritumoral tissue of hypertensive patients, the relationship between the average blood pressure and the RAS peptide and enzymes content had a higher tightness.Conclusion. An increase in the levels of AT1 and AT2, ACE and ACE2 in the tumor tissues and peritumoral tissue in patients with localized KC, regardless of the presence of arterial hypertension at initially higher values in hypertensive patients, was shown. The presence of arterial hypertension in patients with KC changes the metabolism of local RAS in peritumoral tissue and is associated with an increase in the correlation between changes in the components of RAS and arterial hypertension.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2020-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67755690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Expression of growth factors and tyrosine kinase receptors in the primary tumor and tumor thrombus cells in patients with renal cell carcinoma 生长因子和酪氨酸激酶受体在肾细胞癌原发肿瘤和肿瘤血栓细胞中的表达

IF 0.1

Onkourologiya Pub Date : 2020-04-23 DOI: 10.17650/1726-9776-2020-16-1-17-26

M. Volkova, A. Olshanskaya, I. Tsimafeyeu, N. Vashakmadze, Y. Khochenkova, E. Solomko, S. Ashuba, D. Khochenkov, V. Matveev

{"title":"Expression of growth factors and tyrosine kinase receptors in the primary tumor and tumor thrombus cells in patients with renal cell carcinoma","authors":"M. Volkova, A. Olshanskaya, I. Tsimafeyeu, N. Vashakmadze, Y. Khochenkova, E. Solomko, S. Ashuba, D. Khochenkov, V. Matveev","doi":"10.17650/1726-9776-2020-16-1-17-26","DOIUrl":"https://doi.org/10.17650/1726-9776-2020-16-1-17-26","url":null,"abstract":"Objective: to assess the expression and prognostic value of vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2 (FGF-2) and their receptors VEGFR-1, -2; FGFR-1, -2, as well as platelet-derived growth factor receptors (PDGFR-α, PDGFR-β) in paired samples of primary tumors and tumor thrombi in renal cell carcinoma (RCC).Materials and methods. Expression of VEGF-A, FGF-2, VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β was studied in paired surgical samples of primary tumors and tumor thrombi in 25 patients with clear cell RCC pT3a–T4N0–1M0–1 and tumor venous thrombosis by immunohistochemical assay using the appropriate Abcam/Santa Cruz Biotech antibodies from the immunohistochemical staining kit Invitrogen. Expression levels were evaluated by a semi-quantitative method (H-score). The analysis of the correlation between expression levels of VEGF-A, FGF-2, VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β and RCC characteristics, as well as evaluation of their influence on the outcome of RCC were performed.Results. VEGF-A, FGF-2, as well as VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β were expressed in the cytoplasm and on the membrane of the primary tumor and tumor thrombus cells in RCC patients. Tumor thrombus cells were characterized by lower expression of VEGFR-1, VEGFR-2, PDGFR-α (p <0.05 for all) and tendency to lower expression of VEGF-A (p = 0.060), FGF-2 (p = 0.046), FGFR-1 (p = 0.077) and FGFR-2 (p = 0.090) compared with primary tumor cells. RCC Furman grade correlated with the expression levels of VEGFR-1 (p = 0.035) and FGFR-1 (p = 0.022) in the primary tumor cells, tumor invasion into venous wall correlated with the expression levels of VEGFR-1 (p = 0.023) and FGFR-2 (p = 0.005) on the thrombus cells. VEGFR-2 overexpression in the primary tumor cells was associated with significant decrease of overall survival (OS) rate (p = 0.011). There was a tendency to OS deterioration in cases with overexpression of VEGFR-2 (p = 0.093) and VEGF-A (p = 0.095) in the tumor thrombus cells. One-year OS in patients with ³2 identified risk factors was 27.3 %, <2 risk factors – 87.5 % (p = 0.004).Conclusion. Tumor thrombus cells in RCC patients expressed VEGF-A, FGF-2, VEGFR-1, -2; FGFR-1, -2; PDGFR-α, -β less active than the cells of the primary tumor. Overexpression of growth factors and tyrosine kinases correlated with RCC Furman grade and tumor venous wall invasion. Overexpression of VEGFR-2 in both primary tumor and thrombus cells in combination with hypoexpression of VEGF-A in the thrombus negatively influenced on OS.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2020-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67755671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

ВОЗМОЖНЫЙ АЛГОРИТМ ВЕДЕНИЯ БОЛЬНЫХ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ В УСЛОВИЯХ ПАНДЕМИИ КОРОНАВИРУСНОЙ ИНФЕКЦИИ 冠状病毒感染中前列腺癌患者管理的可能算法

IF 0.1

Onkourologiya Pub Date : 2020-04-22 DOI: 10.17650/1726-9776-2020-16-1-124-128

Владимир Борисович Матвеев, Мария Игоревна Волкова, О. П. Трофимова, С. И. Ткачёв

引用次数: 0

Squamous cell carcinoma of the testis and paratesticular tissue 睾丸和睾丸旁组织的鳞状细胞癌

IF 0.1

Onkourologiya Pub Date : 2020-01-16 DOI: 10.17650/1726-9776-2019-15-4-108-112

E. Mamizhev, V. Osetnik, I. B. Dzalilov, B. Aslanov, A. Artemyeva, A. Nosov, S. Gadaev

{"title":"Squamous cell carcinoma of the testis and paratesticular tissue","authors":"E. Mamizhev, V. Osetnik, I. B. Dzalilov, B. Aslanov, A. Artemyeva, A. Nosov, S. Gadaev","doi":"10.17650/1726-9776-2019-15-4-108-112","DOIUrl":"https://doi.org/10.17650/1726-9776-2019-15-4-108-112","url":null,"abstract":"Testicular tumors occur in 1–1.5 % of cases in the structure of the general oncological morbidity among men and constitute 5 % among tumors of the urogenital tract. In Western Europe, 3–6 new cases are recorded a year per 100 thousand male population. Nevertheless, in relation to young men, this particular type of neoplasm is not only the most common oncological pathology (up to 60 % of all neoplasms), but also the main cause of cancer mortality. Risk factors for developing ovarian cancer include a family history, previous development of a tumor in the contralateral testicle, and components of testicular dysgenesis syndrome (cryptorchidism, hypospadias, spermatogenesis disorders leading to infertility). Tumors of paratesticular tissues are much less common and most of them are benign. Squamous cell carcinoma rarely develops as a primary tumor of the testis and / or paratesticular tissue, isolated cases have been described in the English literature. Secondary damage to the scrotum organs is more frequent, but such situations are usually found in patients of an older age group. This article presents the clinical case and the final results of treatment of a patient with squamous cell carcinoma of paratesticular tissue.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2020-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67753955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0